NCT06375473Recruiting
Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
Source: ClinicalTrials.gov · Last updated 6 Jan 2026
Brief summary (registry, in English)
This study is a multi-center observational study.The start time for data collection is May 1, 2024. Patients' baseline and treatment data will be collected under informed concent. The purpose of this case registry study was to evaluate the safety and efficacy of irinotecan hydrochloride liposome injection II based therapy in Chinese patients with pancreatic cancer in the real world by collecting, understanding, and analyzing the etiology, clinical features, treatment pattern, treatment outcomes, and pharmacoeconomics changes in pancreatic cancer patients receiving this regimen.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 3000 (estimated)
- First submitted
- 16 Apr 2024
- Start date
- 19 Apr 2024
- Primary completion date
- 19 Apr 2027
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Pancreatic cancer
- NCT number
- NCT06375473
What you commit to
- Study type: Observational
- Planned participants: 3000
- From 19 Apr 2024 to the primary completion date, 19 Apr 2027
- 10 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- The researchers determined that other conditions were not suitable for inclusion in the study.
Other
- Confirmed pregnant or lactating women;
Who the study is looking for
- Patients with pancreatic ductal adenocarcinoma diagnosed by pathology or imaging;
- Age ≥18 years old, male or female;
- Patients receiving treatment based on irinotecan hydrochloride liposome injection II;
- The subjects voluntarily joined the study and signed the informed consent.
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking Union Medical College Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| Peking Unicersity First Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| Anhui Provincial Cancer Hospital Coordinator of this site? Confirm its status | Hefei | China | Recruiting |
| Henan Provincial People's Hospital Coordinator of this site? Confirm its status | Henan | China | Recruiting |
| The First Affiliated Hospital of Guangxi Medical University Coordinator of this site? Confirm its status | Nanning | China | Recruiting |
| Ningbo Medical Center Lihuili Hospital Coordinator of this site? Confirm its status | Ningbo | China | Recruiting |
| RenJi Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
| Wuhan Union Hospital of China Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
| The First Affiliated Hospital of Zhengzhou University Coordinator of this site? Confirm its status | Zhengzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.